SG11201808085WA - Protease-activated t cell bispecific molecules - Google Patents

Protease-activated t cell bispecific molecules

Info

Publication number
SG11201808085WA
SG11201808085WA SG11201808085WA SG11201808085WA SG11201808085WA SG 11201808085W A SG11201808085W A SG 11201808085WA SG 11201808085W A SG11201808085W A SG 11201808085WA SG 11201808085W A SG11201808085W A SG 11201808085WA SG 11201808085W A SG11201808085W A SG 11201808085WA
Authority
SG
Singapore
Prior art keywords
protease
international
idiotype
activatable
roche
Prior art date
Application number
SG11201808085WA
Inventor
Peter Bruenker
Rebecca Croasdale-Wood
Christian Klein
Juergen Michael Schanzer
Kay-Gunnar Stubenrauch
Pablo Umana
Martina Geiger
Eric Sullivan
Jigar Patel
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of SG11201808085WA publication Critical patent/SG11201808085WA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • C07K16/4258—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Abstract

FcKnob) PG LALA Fc(Hole) P329G LALA = (54) Title: PROTEASE-ACTIVATED T CELL BISPECIFIC MOLECULES FIG. 1A Protease site with GS linker Anti CD3 scFv 4.15.64 anti-CD3 V CH1 Common Light Chain 7859 W O 20 17 / 16 25 87 Al (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2017/162587 Al 28 September 2017 (28.09.2017) WIPO I PCT IIIII111111110111011111111111$111110 011IIIIII0111111111110111111111111111 (51) International Patent Classification: C07K 16/46 (2006.01) C07K 16/30 (2006.01) C07K 16/42 (2006.01) C07K 16/32 (2006.01) C07K 16/28 (2006.01) (21) International Application Number: PCT/EP2017/056556 (22) International Filing Date: 20 March 2017 (20.03.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 16161740.2 22 March 2016 (22.03.2016) EP 62/433,327 13 December 2016 (13.12.2016) US (71) Applicant (for all designated States except US): F. HOFF- MANN-LA ROCHE AG [CH/CH]; Grenzacherstrasse 124, 4070 Basel (CH). (71) Applicant US only): HOFFMANN-LA ROCHE INC. [US/US]; Overlook at Great Notch, 150 Clove Road, 8th Floor, Suite 8 - Legal Department, Little Falls, New Jersey 07424 (US). (72) Inventors: BRUENKER, Peter; Burgwiesenstrasse 3c, 8335 Hittnau (CH). CROASDALE-WOOD, Rebecca; 39 college close, Longridge, Preston Lancashire PR3 3AX (GB). KLEIN, Christian; Chapfstrasse 26B, 8906 Bon- stetten (CH). SCHANZER, Juergen Michael; Metzstr. 26, 81667 Mlinchen (DE). STUBENRAUCH, Kay-Gun- nar; Parkstrasse la, 82377 Penzberg (DE). UMANA, Pablo; Felsenrainstrasse 28, 8832 Wollerau (CH). GEI- GER, Martina; Muehlestrasse 4a, 8912 Obfelden (CH). SULLIVAN, Eric; c/o Roche Sequencing Solutions, Inc., 4300 Hacienda Drive, Pleasanton, California 94588 (US). PATEL, Jigar; c/o Roche Sequencing Solutions, Inc., 4300 Hacienda Drive, Pleasanton, California 94588 (US). (74) Agent: BRODBECK, Michel; Grenzacherstrasse 124, 4070 Basel (CH). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, [Continued on next page] (57) : The present invention generally relates to novel protease-activatable T cell activating bispecific molecules and idiotype-specific poly- peptides acting as masking moieties. The present in- vention also relates to polynucleotides encoding such protease-activatable T cell activating bispecific mo- lecules and idiotype-specific polypeptides, and vec- tors and host cells comprising such polynucleotides. The invention further relates to methods for produ- cing the protease-activatable T cell activating bispe- cific molecules and idiotype-specific polypeptides of the invention, and to methods of using these pro- tease-activatable T cell activating bispecific mo- lecules and idiotype-specific polypeptides in the treatment of disease. WO 2017/162587 Al MIDEDIMOMOIDEIRMEMOMOHEIHIONDERVOIMIE DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: — of inventorship (Rule 4.17(iv)) Published: with international search report (Art. 21(3)) with sequence listing part of description (Rule 5.2(a))
SG11201808085WA 2016-03-22 2017-03-20 Protease-activated t cell bispecific molecules SG11201808085WA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16161740 2016-03-22
US201662433327P 2016-12-13 2016-12-13
PCT/EP2017/056556 WO2017162587A1 (en) 2016-03-22 2017-03-20 Protease-activated t cell bispecific molecules

Publications (1)

Publication Number Publication Date
SG11201808085WA true SG11201808085WA (en) 2018-10-30

Family

ID=55646332

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201808085WA SG11201808085WA (en) 2016-03-22 2017-03-20 Protease-activated t cell bispecific molecules

Country Status (14)

Country Link
EP (1) EP3433280B1 (en)
KR (1) KR102444614B1 (en)
CN (1) CN108884170A (en)
AR (2) AR107946A1 (en)
AU (1) AU2017237376B2 (en)
BR (1) BR112018016281A2 (en)
CA (1) CA3012422A1 (en)
CO (1) CO2018007556A2 (en)
CR (1) CR20180453A (en)
MA (1) MA43724B1 (en)
PE (1) PE20181891A1 (en)
PT (1) PT3433280T (en)
SG (1) SG11201808085WA (en)
WO (1) WO2017162587A1 (en)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3298033T (en) 2015-05-18 2020-09-22 Tcr2 Therapeutics Inc Compositions and methods for tcr reprogramming using fusion proteins
KR20240018673A (en) 2016-11-28 2024-02-13 추가이 세이야쿠 가부시키가이샤 Antigen-binding domain, and polypeptide including conveying section
CA3054304A1 (en) * 2017-02-22 2018-08-30 Aleta Biotherapeutics Inc. Compositions and methods for treatment of cancer
CN111247171A (en) 2017-10-14 2020-06-05 西托姆克斯治疗公司 Antibodies, activatable antibodies, bispecific antibodies and bispecific activatable antibodies and methods of use thereof
SG11202004627WA (en) * 2017-11-28 2020-06-29 Chugai Pharmaceutical Co Ltd Ligand-binding molecule having adjustable ligand-binding activity
SG11202004897XA (en) * 2017-11-28 2020-06-29 Chugai Pharmaceutical Co Ltd Polypeptide including antigen-binding domain and carrying section
WO2019113385A1 (en) * 2017-12-07 2019-06-13 Janux Therapeutics, Inc. Modified t cell receptors
AR115360A1 (en) * 2018-02-08 2021-01-13 Genentech Inc ANTIGEN BINDING MOLECULES AND METHODS OF USE
KR20210020903A (en) * 2018-05-14 2021-02-24 하푼 테라퓨틱스, 인크. Binding moieties for conditional activation of immunoglobulin molecules
WO2019222275A2 (en) * 2018-05-14 2019-11-21 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using inducible fusion proteins
KR20210038548A (en) 2018-06-22 2021-04-07 큐진 인크. Cytokine-based bioactive drugs and methods of use thereof
EP3834849A4 (en) * 2018-07-24 2022-08-03 CRAGE medical Co., Limited Method for treating tumor using immune effector cell
MX2021003554A (en) 2018-09-25 2021-05-27 Harpoon Therapeutics Inc Dll3 binding proteins and methods of use.
CN113603783B (en) 2018-12-21 2022-07-12 浙江时迈药业有限公司 Protease cleavable bispecific antibodies and uses thereof
EP3950713A4 (en) * 2019-03-29 2023-08-09 Green Cross Corporation Fusion protein comprising anti-mesothelin antibody, anti-cd3 antibody or anti-egfr antibody, bispecific or trispecific antibody comprising same, and uses thereof
GB201906685D0 (en) * 2019-05-13 2019-06-26 Ultrahuman Six Ltd Activatable protein constructs and uses thereof
CN113905757A (en) * 2019-06-05 2022-01-07 中外制药株式会社 Antibody cleavage site binding molecules
EP3983432A1 (en) * 2019-06-12 2022-04-20 Askgene Pharma, Inc. Novel il-15 prodrugs and methods of use thereof
CA3147690A1 (en) * 2019-07-19 2021-01-28 WuXi Biologics Ireland Limited Polypeptide complex for conjugation and use thereof
MX2022011780A (en) 2020-04-09 2022-11-10 Cytomx Therapeutics Inc Compositions containing activatable antibodies.
BR112022022369A2 (en) 2020-05-04 2023-03-14 Immunorizon Ltd PRECURSO TRI-SPECIFIC ANTIBODY CONSTRUCTS AND METHODS OF THEIR USE
IL296429A (en) * 2020-06-19 2022-11-01 Hoffmann La Roche Protease-activated t cell bispecific antibodies
WO2022170619A1 (en) * 2021-02-11 2022-08-18 Adagene Pte. Ltd. Anti-cd3 antibodies and methods of use thereof
US20230174995A1 (en) * 2021-10-15 2023-06-08 Cytomx Therapeutics, Inc. Activatable polypeptide complex
WO2023064927A1 (en) * 2021-10-15 2023-04-20 Cytomx Therapeutics, Inc. Activatable polypeptide complex
WO2023186760A1 (en) * 2022-03-28 2023-10-05 F. Hoffmann-La Roche Ag Improved folr1 protease-activatable t cell bispecific antibodies
WO2023192973A1 (en) * 2022-04-01 2023-10-05 Cytomx Therapeutics, Inc. Activatable multispecific molecules and methods of use thereof
WO2023220647A1 (en) 2022-05-11 2023-11-16 Regeneron Pharmaceuticals, Inc. Multispecific binding molecule proproteins and uses thereof
WO2023222580A1 (en) 2022-05-16 2023-11-23 Byondis B.V. Novel masked antibodies
CN116462768B (en) * 2023-06-13 2023-09-22 浙江时迈药业有限公司 Bispecific antibodies against FOLR1 and uses thereof

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1156905B (en) 1977-04-18 1987-02-04 Hitachi Metals Ltd ORNAMENT ITEM SUITABLE TO BE FIXED USING A PERMANENT MAGNET
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
JP2919890B2 (en) 1988-11-11 1999-07-19 メディカル リサーチ カウンスル Single domain ligand, receptor consisting of the ligand, method for producing the same, and use of the ligand and the receptor
DE3920358A1 (en) 1989-06-22 1991-01-17 Behringwerke Ag BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
DK0590058T3 (en) 1991-06-14 2004-03-29 Genentech Inc Humanized heregulin antibody
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
ES2136092T3 (en) 1991-09-23 1999-11-16 Medical Res Council PROCEDURES FOR THE PRODUCTION OF HUMANIZED ANTIBODIES.
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
EP1997894B1 (en) 1992-02-06 2011-03-30 Novartis Vaccines and Diagnostics, Inc. Biosynthetic binding protein for cancer marker
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
ES2375931T3 (en) 1997-12-05 2012-03-07 The Scripps Research Institute HUMANIZATION OF ANTIBODY MURINO.
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
MXPA02003456A (en) 1999-10-04 2002-10-23 Medicago Inc Method for regulating transcription of foreign genes in the presence of nitrogen.
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
US7432063B2 (en) 2002-02-14 2008-10-07 Kalobios Pharmaceuticals, Inc. Methods for affinity maturation
JP5128935B2 (en) 2004-03-31 2013-01-23 ジェネンテック， インコーポレイテッド Humanized anti-TGF-β antibody
EP2360186B1 (en) 2004-04-13 2017-08-30 F. Hoffmann-La Roche AG Anti-P-selectin antibodies
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
DK1871805T3 (en) 2005-02-07 2019-12-02 Roche Glycart Ag ANTI-BINDING MOLECULES BINDING EGFR, VECTORS CODING THEREOF, AND APPLICATIONS THEREOF
WO2006099141A2 (en) * 2005-03-10 2006-09-21 Morphotek, Inc. Anti-mesothelin antibodies
US8592562B2 (en) 2008-01-07 2013-11-26 Amgen Inc. Method for making antibody Fc-heterodimeric molecules using electrostatic steering effects
DK2691417T3 (en) 2011-03-29 2018-11-19 Roche Glycart Ag ANTIBODY FC VARIANTS
GB201203442D0 (en) * 2012-02-28 2012-04-11 Univ Birmingham Immunotherapeutic molecules and uses
US20140004121A1 (en) * 2012-06-27 2014-01-02 Amgen Inc. Anti-mesothelin binding proteins
US20140302037A1 (en) * 2013-03-15 2014-10-09 Amgen Inc. BISPECIFIC-Fc MOLECULES
AU2014236769B2 (en) * 2013-03-15 2018-09-27 Amgen Inc. Heterodimeric bispecific antibodies
US20140308285A1 (en) * 2013-03-15 2014-10-16 Amgen Inc. Heterodimeric bispecific antibodies
UA119646C2 (en) * 2013-07-05 2019-07-25 Ґенмаб А/С Humanized or chimeric cd3 antibodies
PT3406633T (en) * 2013-07-25 2022-05-04 Cytomx Therapeutics Inc Multispecific antibodies, multispecific activatable antibodies and methods of using the same
US20160257748A1 (en) * 2013-09-25 2016-09-08 Amgen Inc. V-c-fc-v-c antibody
EP3172235A2 (en) * 2014-07-25 2017-05-31 Cytomx Therapeutics Inc. Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same
EP2982692A1 (en) * 2014-08-04 2016-02-10 EngMab AG Bispecific antibodies against CD3epsilon and BCMA
SG11201703803WA (en) * 2014-11-11 2017-06-29 Amunix Operating Inc Targeted xten conjugate compositions and methods of making same
MX2017006626A (en) * 2014-11-20 2017-08-21 Hoffmann La Roche Common light chains and methods of use.
US11485791B2 (en) * 2015-03-17 2022-11-01 Tilt Biotherapeutics Oy Oncolytic adenoviruses coding for bi-specific antibodies

Also Published As

Publication number Publication date
PE20181891A1 (en) 2018-12-11
MA43724B1 (en) 2023-06-28
PT3433280T (en) 2023-06-15
AR107946A1 (en) 2018-06-28
MA43724A (en) 2018-11-28
AU2017237376A1 (en) 2018-08-02
WO2017162587A1 (en) 2017-09-28
AU2017237376B2 (en) 2024-03-07
KR102444614B1 (en) 2022-09-21
BR112018016281A2 (en) 2019-01-02
CN108884170A (en) 2018-11-23
EP3433280B1 (en) 2023-04-19
KR20180128407A (en) 2018-12-03
AR120543A2 (en) 2022-02-23
CO2018007556A2 (en) 2018-07-31
EP3433280A1 (en) 2019-01-30
CR20180453A (en) 2018-12-05
CA3012422A1 (en) 2017-09-28

Similar Documents

Publication Publication Date Title
SG11201808085WA (en) Protease-activated t cell bispecific molecules
SG11201908787WA (en) Novel bispecific antigen binding molecules capable of specific binding to cd40 and to fap
SG11201909154SA (en) Bispecific antibodies specifically binding to pd1 and lag3
SG11201908719QA (en) Biomarkers and car t cell therapies with enhanced efficacy
SG11201810777WA (en) Purification of multispecific antibodies
SG11201908088RA (en) Antibodies against pd-l1
SG11201805784PA (en) Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
SG11201810076WA (en) Antigen binding molecules comprising a tnf family ligand trimer and pd1 binding moiety
SG11201900885VA (en) Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule
SG11201908784TA (en) Improved antigen binding receptor formats
SG11201808261RA (en) Genetic variant-phenotype analysis system and methods of use
SG11201908796XA (en) Improved antigen binding receptors
SG11201809522WA (en) Method of nucleic acid sequence determination
SG11201903857UA (en) Antibodies to pd-1 and uses thereof
SG11201901528RA (en) Proteolytically cleavable chimeric polypeptides and methods of use thereof
SG11201908489XA (en) De novo synthesized combinatorial nucleic acid libraries
SG11201903454VA (en) Immunologically discernible cell surface variants for use in cell therapy
SG11201906192SA (en) Methods of treating cancer with anti-pd-1 antibodies
SG11201811025VA (en) Systems and methods for automated annotation and screening of biological sequences
SG11201806282XA (en) High-throughput identification of patient-specific neoepitopes as therapeutic targets for cancer immunotherapies
SG11201807176XA (en) TGFß1-BINDING IMMUNOGLOBULINS AND USE THEREOF
SG11201909656YA (en) Intracellular kinase associated with resistance against anti-tumour immune responses, and uses thereof
SG11201407669QA (en) Methods for improving safety of blood-brain barrier transport
SG11201907364WA (en) Anti-tryptase antibodies, compositions thereof, and uses thereof
SG11201906553TA (en) Methods and reagents for synthesising polynucleotide molecules